Just In
- 7 hrs ago Heeramandi Screening: Alia Bhatt, Ananya Panday, Rashmika Mandanna And Others Serve Finest Ethnic Style!
- 8 hrs ago From Alia Bhatt To Kriti Sanon, Korean Beauty Products That Bollywood Divas Swear By
- 11 hrs ago Exclusive: On World Malaria Day 2024, Dr Shares Danger Signs Parents Must Watch Out For In Child With Malaria
- 11 hrs ago Exclusive: Expert Debunks 5 Common Misconceptions About Expectant Mothers That You Need To Steer Clear From
Don't Miss
- Movies Arti Singh Wedding: Groom Dipak Chauhan’s First Look Out As He Reaches Venue With Baraat - VIRAL VIDEOS
- Sports T20 World Cup 2024: Waqar Younis Predicts Pakistan's 15-Man Squad; Drops This Express Pacer
- Finance 1:5 Stock Split Approved: Defence Stock To Be Cheaper Soon, Shares Zoom 507% In 1-Yr
- News King Charles Grants Royal Assent: UK's Rwanda Deportation Plan Now Law
- Automobiles Royal Enfield Unveils Revolutionary Rentals & Tours Service: Check Out All Details Here
- Technology Elon Musk’s X Is Launching a TV App Similar to YouTube for Watching Videos
- Education AICTE introduces career portal for 3 million students, offering fully-sponsored trip to Silicon Valley
- Travel Escape to Kalimpong, Gangtok, and Darjeeling with IRCTC's Tour Package; Check Itinerary
Corbevax Will Be Allowed As A Booster For Those Fully Vaccinated With Covishield Or Covaxin
Allowing Biological E's Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet on Tuesday, sources said.
The Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precaution dose for those aged 18 and above. India's first indigenously-developed RBD protein subunit vaccine, Corbevax, is currently being used to inoculate children in the age group of 12 to 14 years.
"The National Technical Advisory Group on Immunisation (NTAGI) will discuss allowing Corbevax, which has been cleared by the DCGI, as a booster for those fully vaccinated with Covishield or Covaxin," a source told PTI.
The government advisory panel is also expected to review the trial data of the country's first quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer, developed by the Serum Institute of India.
A separate HPV working group of the NTAGI had, on June 8, examined the vaccine's clinical trial data and usefulness for inclusion in the national immunisation programme, sources had said.
The recommendation of the Standing Technical Sub-Committee (STSC) of the NTAGI on reducing the gap between the second dose and the precaution dose of Covid vaccines from nine to six months may also be ratified at the meeting to be chaired by the Union health secretary. PTI PLB RC
- wellnessNTAGI To Review Covaxin Corbevax Data For 6-12 Years Thursday, Discuss Reducing Booster Dose Gap
- wellnessBiological E Ltd Reduces Price Of Its Covid-19 Vaccine Corbevax To Rs 250 Per Dose
- kidsCovid-19 Vaccines For Kids: DCGI Grants Emergency Use Nod To 3 Vaccines For Different Age Group Of Children
- kidsCOVID-19 Vaccine: Government Panel Recommends EUA For Corbevax For Kids Between 5-11 Years Age Groups
- wellnessCOVID-19: DGCI Grants Restricted Emergency-Use Nod To Corbevax Vaccine For 12-18 Age Group
- wellnessCorbevax: What Do We Know About Biological E's New COVID-19 Vaccine?
- healthIndia-US Healthcare Collaboration In Spotlight As India Approves Two More Covid-19 Vaccines
- healthPanel Recommends EUA For Covid-19 Vaccines Covovax, Corbevax And Anti-Covid Pill Molnupiravir
- healthBiological E Hopes To Roll Out COVID-19 Vaccine Corbevax By November-End
- healthCOVID-19 Vaccines and Heart Attacks: New Studies Show Different Results; What Are They?
- wellnessBooster Dose Of COVID Vaccine Needed To Fight Against Omicron: Study
- wellnessCovishield Dose Gap Reduced To 8-16 Weeks From 12-16